INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE EVIDENCE INDEX

The Study Library.

8,456 peer-reviewed studies, each with a short note written from its published abstract: what kind of study it was, who took part, what was measured and what the authors reported. Observational studies show associations, not proof.

Showing studies that examined tomatoes. Clear

People assigned to a diet, food or program and measured.

2 studies

2020 / In vitro study and pilot controlled clinical study

In a pilot study of postmenopausal women, consuming lycopene-rich tomato sauce prevented significant bone density loss compared to controls.

Researchers evaluated the in vitro effects of lycopene on Saos-2 osteoblast cells and conducted a pilot controlled trial assessing bone loss prevention via lycopene-rich tomato sauce in 39 postmenopausal women. In vitro, lycopene modulated Wnt/β-catenin, ERK 1/2, RUNX2, COL1A, and RANKL pathways. In the clinical trial, significant bone density loss was not detected in women consuming tomato sauce, whereas controls experienced bone loss (p = 0.002). Tomato sauce intake also led to a greater reduction in bone alkaline phosphatase compared with controls (18% vs 8.5%, p = 0.03).

Russo C, Ferro Y, Maurotti S, et al. J Transl Med, 2020. PMID 31996227

2011 / Randomized controlled trial

Lycopene supplementation significantly reduced oxidative stress parameters and the bone resorption marker NTx in postmenopausal women.

Sixty postmenopausal women underwent a 1-month washout and were then randomized to regular tomato juice (30 mg lycopene/day), lycopene-rich tomato juice (70 mg/day), Lyc-O-Mato capsules (30 mg/day), or placebo capsules for 4 months. Participants receiving tomato juice or lycopene capsules were analyzed together as a lycopene-supplemented group. Compared to placebo, 4 months of lycopene supplementation significantly increased serum lycopene (p < 0.001) and total antioxidant capacity (p < 0.05). Lycopene also led to significant reductions in lipid peroxidation (p < 0.05 vs placebo change), protein oxidation (p < 0.005 vs placebo change), and the bone resorption marker NTx (p < 0.02 vs placebo change).

Mackinnon ES, Rao AV, Josse RG, et al. Osteoporos Int, 2011. PMID 20552330